Abstract
Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted by the gut in response to food and helps in reducing post-prandial glucose exertion. It achieves this through a number of mechanisms, including stimulating insulin release by pancreatic β-cells in a glucose-dependent manner; inhibition of glucagon release by pancreatic α-cells (also in a glucose-dependent manner); induction of central appetite suppression and by delaying gastric empting thereby inducing satiety and also reducing the rate of absorption of nutrients. However, GLP1 receptors have been described in a number of extra-pancreatic tissues, including the endothelium and the myocardium. This suggests that the physiological effects of GLP1 extend beyond post-prandial glucose control and raises the possibility that GLP1 might have cardiovascular effects. This is of importance in our understanding of incretin hormone physiology and especially because of the possible implications that it might have with regard to cardiovascular effects of incretin-based therapies, namely DPP-IV inhibitors (gliptins) and GLP1 analogues. This review analyzes the animal and human data on the effects of GLP1 on the cardiovascular system in health and in disease and the currently available data on cardiovascular effects of incretin-based therapies. It is the author’s view that the physiological role of GLP1 is not only to minimize postprandial hypoglycaemia, but also protect against it.
Keywords: Cardiovascular, glucagon-like peptide 1, incretin.
Current Diabetes Reviews
Title:Glucagon-Like Peptide 1 and the Cardiovascular System
Volume: 10 Issue: 5
Author(s): Stephen Fava
Affiliation:
Keywords: Cardiovascular, glucagon-like peptide 1, incretin.
Abstract: Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted by the gut in response to food and helps in reducing post-prandial glucose exertion. It achieves this through a number of mechanisms, including stimulating insulin release by pancreatic β-cells in a glucose-dependent manner; inhibition of glucagon release by pancreatic α-cells (also in a glucose-dependent manner); induction of central appetite suppression and by delaying gastric empting thereby inducing satiety and also reducing the rate of absorption of nutrients. However, GLP1 receptors have been described in a number of extra-pancreatic tissues, including the endothelium and the myocardium. This suggests that the physiological effects of GLP1 extend beyond post-prandial glucose control and raises the possibility that GLP1 might have cardiovascular effects. This is of importance in our understanding of incretin hormone physiology and especially because of the possible implications that it might have with regard to cardiovascular effects of incretin-based therapies, namely DPP-IV inhibitors (gliptins) and GLP1 analogues. This review analyzes the animal and human data on the effects of GLP1 on the cardiovascular system in health and in disease and the currently available data on cardiovascular effects of incretin-based therapies. It is the author’s view that the physiological role of GLP1 is not only to minimize postprandial hypoglycaemia, but also protect against it.
Export Options
About this article
Cite this article as:
Fava Stephen, Glucagon-Like Peptide 1 and the Cardiovascular System, Current Diabetes Reviews 2014; 10 (5) . https://dx.doi.org/10.2174/1573399810666141030125830
DOI https://dx.doi.org/10.2174/1573399810666141030125830 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Life-history Constraints on the Mechanisms that Control the Rate of ROS Production
Current Genomics Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Anti Diabetic Evaluation of Methanolic Extract of <i>Psoralea corylifolia</i> L. & <i>Psoralea esculenta</i> L. Seeds in Streptozotocin Induced Diabetic Rats and Histopathological Changes in Diabetic Rats Pancreas: A Comparative Study
The Natural Products Journal The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry